UK Clinical Trials Showing Signs Of Recovery But Global Ranking Still Poor
While things are starting to look up for the commercial clinical trial ecosystem in the UK, more progress is needed to improve industry’s confidence in the country as a destination for research, especially revenue-generating Phase III trials.
You may also be interested in...
The UK is seeing the benefits of moving away from its earlier “bespoke” approach to the costing of commercial trials run in the National Health Service. Standardization has helped reduce study set up times by around four months.
The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial more of their products in the National Health Service.
The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.